X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PLETHICO PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PLETHICO PHARMA GLENMARK PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 13.5 -1.1 - View Chart
P/BV x 2.4 0.0 14,436.9% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 GLENMARK PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
PLETHICO PHARMA
Mar-14
GLENMARK PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs930395 235.5%   
Low Rs51731 1,653.0%   
Sales per share (Unadj.) Rs322.6604.4 53.4%  
Earnings per share (Unadj.) Rs28.532.5 87.7%  
Cash flow per share (Unadj.) Rs39.251.3 76.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0473.6 38.6%  
Shares outstanding (eoy) m282.1734.08 828.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.4 636.2%   
Avg P/E ratio x25.46.6 387.2%  
P/CF ratio (eoy) x18.54.2 444.8%  
Price / Book Value ratio x4.00.5 878.8%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2067,262 2,811.8%   
No. of employees `00013.7NA-   
Total wages/salary Rs m18,7181,596 1,172.8%   
Avg. sales/employee Rs Th6,636.8NM-  
Avg. wages/employee Rs Th1,364.7NM-  
Avg. net profit/employee Rs Th586.1NM-  
INCOME DATA
Net Sales Rs m91,03120,598 441.9%  
Other income Rs m914386 236.6%   
Total revenues Rs m91,94520,984 438.2%   
Gross profit Rs m16,1542,818 573.3%  
Depreciation Rs m3,019642 470.0%   
Interest Rs m2,8561,593 179.2%   
Profit before tax Rs m11,193969 1,155.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155-138 -2,279.7%   
Profit after tax Rs m8,0391,107 726.2%  
Gross profit margin %17.713.7 129.7%  
Effective tax rate %28.2-14.3 -197.2%   
Net profit margin %8.85.4 164.3%  
BALANCE SHEET DATA
Current assets Rs m69,88718,877 370.2%   
Current liabilities Rs m32,87911,896 276.4%   
Net working cap to sales %40.733.9 120.0%  
Current ratio x2.11.6 134.0%  
Inventory Days Days8136 226.6%  
Debtors Days Days93198 47.3%  
Net fixed assets Rs m28,8929,861 293.0%   
Share capital Rs m282341 82.8%   
"Free" reserves Rs m51,35312,331 416.5%   
Net worth Rs m51,63516,139 319.9%   
Long term debt Rs m41,4184,706 880.1%   
Total assets Rs m125,95433,146 380.0%  
Interest coverage x4.91.6 306.0%   
Debt to equity ratio x0.80.3 275.1%  
Sales to assets ratio x0.70.6 116.3%   
Return on assets %8.68.1 106.2%  
Return on equity %15.66.9 227.0%  
Return on capital %15.112.3 122.9%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m36,3174,402 824.9%   
Fx outflow Rs m9,7203,184 305.3%   
Net fx Rs m26,5981,219 2,182.8%   
CASH FLOW
From Operations Rs m16,4812,437 676.2%  
From Investments Rs m-10,133-6,265 161.8%  
From Financial Activity Rs m-4,6852,490 -188.1%  
Net Cashflow Rs m1,770-1,337 -132.4%  

Share Holding

Indian Promoters % 48.3 82.7 58.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.3 160.5%  
FIIs % 34.4 5.5 625.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 7.5 140.0%  
Shareholders   56,727 10,665 531.9%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALKEM LABORATORIES  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON   

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views on News

PC JEWELLER Plunges by 5%; BSE 500 Index Down 0.2% (Market Updates)

Jun 24, 2019 | Updated on Jun 24, 2019

PC JEWELLER share price has plunged by 5% and its current market price is Rs 57. The BSE 500 is down by 0.2%. The top gainers in the BSE 500 Index are JAIN IRRIGATION (up 13.7%) and SUZLON ENERGY (up 10.3%). The top losers are PC JEWELLER (down 5.2%) and GLENMARK PHARMA (down 7.6%).

GLENMARK PHARMA Plunges by 5%; BSE HEALTHCARE Index Flat (Market Updates)

Jun 24, 2019 | Updated on Jun 24, 2019

GLENMARK PHARMA share price has plunged by 5% and its current market price is Rs 495. The BSE HEALTHCARE is down by 0.0%. The top gainers in the BSE HEALTHCARE Index are PIRAMAL ENTERPRISES (up 4.0%) and LUPIN (up 2.8%). The top losers is GLENMARK PHARMA (down 5.5%).

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 24, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS